Ultomiris 300 mg/3 mL (100 mg/mL) injection Images
Generic Name: ravulizumab
This medication has been identified as Ultomiris 300 mg/3 mL (100 mg/mL) injection. It is supplied by Alexion Pharmaceuticals Inc.
Ultomiris is used in the treatment of Myasthenia Gravis; Hemolytic Uremic Syndrome; Paroxysmal Nocturnal Hemoglobinuria; Neuromyelitis Optica Spectrum Disorder and belongs to the drug class selective immunosuppressants. Ultomiris 300 mg/3 mL (100 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Ultomiris
- Generic Name
- ravulizumab
- Strength
- 300 mg/3 mL (100 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Selective immunosuppressants
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Alexion Pharmaceuticals Inc.
- National Drug Code (NDC)
- 25682-0025
More about Ultomiris (ravulizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (5)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
